Serina Therapeutics (SER) Investor presentation summary

Key scientific findings

• Anaphylaxis from mRNA vaccines is linked to high titers of IgG and IgM antibodies against PEG, leading to basophil degranulation and increased systemic reactogenicity.

• PEG in lipid nanoparticles (LNPs) is identified as the main trigger for these immune responses, with Moderna vaccines inducing higher antibody titers than Pfizer.

• Anti-PEG antibodies can activate complement, compromise LNP integrity, and increase adverse events.

• Substituting PEG-lipids with PEOZ-lipids in LNPs results in similar biophysical properties but fails to elicit IgM or IgG responses, even after repeat dosing.

• PEOZ-LNPs selectively target antigen-presenting cells and may reduce adverse immune reactions.

Preclinical and clinical data

• Human and animal studies confirm that mRNA-LNP vaccines boost anti-PEG IgG and IgM, correlating with increased systemic reactogenicity.

• PEG-LNPs show accelerated blood clearance (ABC) on repeat dosing, while PEOZ-LNPs show much less ABC and minimal antibody induction.

• Rat studies demonstrate that PEOZ-LNPs do not induce anti-PEG antibodies, unlike PEG-LNPs.

• Biophysical properties such as size, polydispersity, and encapsulation efficiency are nearly identical between PEG-LNPs and PEOZ-LNPs.

• PEOZ-LNPs maintain payload delivery and selective immune cell targeting in vivo.

Platform and technology implications

• The POZ Platform enables improved delivery for small molecules, RNA, and antibody-drug conjugates by reducing immunogenicity and enhancing targeting.

• PEOZ-lipid LNPs represent a novel approach for next-generation mRNA vaccines and therapeutics, potentially overcoming limitations of current PEG-based systems.

• Selective targeting of antigen-presenting cells by PEOZ-LNPs could enhance vaccine efficacy and safety.

• The technology is positioned to advance future vaccine generations with reduced adverse events.

• Collaboration with leading academic labs supports the platform's validation and development.